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Abstract 
The metabolic syndrome encompasses metabolic and cardiovascular risk factors which predict 
diabetes and cardiovascular disease (CVD) better than any of its individual components. 
Nonalcoholic fatty liver disease (NAFLD) comprises a disease spectrum which includes variable 
degrees of simple steatosis (nonalcoholic fatty liver, NAFL), nonalcoholic steatohepatitis (NASH) 
and cirrhosis. NAFLD is the hepatic manifestation of the metabolic syndrome, with insulin 
resistance as the main pathogenetic mechanism. Recent data indicate that hyperinsulinemia is 
probably the consequence rather than cause of NAFLD and NAFLD can be considered an 
independent predictor of cardiovascular disease. Serum free fatty acids derived from lipolysis of 
visceral adipose tissue are the main source of hepatic triglycerides in NAFLD, although hepatic de 
novo lipogenesis and dietary fat supply contribute to the pathogenesis of NAFLD. Approximately 
10–25% NAFLD patients develop NASH, the evolutive form of hepatic steatosis. Presumably in a 
genetically predisposed environment, this increased lipid overload overwhelms the oxidative 
capacity and reactive oxygen species are generated, leading to lipid peroxidation, cytokine 
induction, chemoattraction of inflammatory cells, hepatic stellate cell activation and finally 
fibrogenesis with extracellular matrix deposition. No currently available therapies for NAFLD and 
NASH exist. Recently nuclear receptors have emerged as key regulators of lipid and carbohydrate 
metabolism for which specific pharmacological ligands are available, making them attractive 
therapeutic targets for NAFLD and NASH. 
 
Abbreviations 
ALT, alanine aminotransferase; BMI, body mass index; CVD, cardiovascular disease; FFA, free 
fatty acids; HDL, high density lipoprotein; 1H-MRS, proton magnetic resonance spectroscopy; IDF, 
International Diabetes Federation; LDL, low density lipoprotein; NAFLD, nonalcoholic fatty liver 
disease; SNP, single nucleotide polymorphism; VLDL, very low density lipoprotein 
 
1. Introduction 
The metabolic syndrome is a cluster of metabolic and cardiovascular risk factors which predicts 
diabetes and cardiovascular disease (CVD) better than any of its individual components [1]. The 
latest definition of the metabolic syndrome by International Diabetes Federation (IDF) includes 
abdominal obesity defined by increased waist circumference (≥94 cm in men and ≥80 cm in 
women) and two or more of the following features: elevated blood pressure, fasting glucose or 
triglyceride concentrations, or low HDL cholesterol [1]. The term nonalcoholic fatty liver disease 
(NAFLD) comprises a disease spectrum which includes variable degrees of simple steatosis 
(nonalcoholic fatty liver, NAFL), nonalcoholic steatohepatitis (NASH) and cirrhosis [2] and [3]. 
NAFLD can be considered the hepatic manifestation of the metabolic syndrome. Simple steatosis is 
benign, whereas NASH is defined by the presence of hepatocyte injury, inflammation and/or 
fibrosis which can lead to cirrhosis, liver failure and hepatocellular carcinoma. In contrast to the 
metabolic syndrome, the definition of nonalcoholic fatty liver disease (NAFLD) includes only one 
component: liver fat content >5–10% by weight in the absence of excess alcohol consumption or 
any other liver disease. This review discuss the pathogenetic link between insulin resistance, the 
metabolic syndrome and fat accumulation in the liver (NAFLD), and the mechanisms leading to the 
shift from NAFLD to NASH. 
 
2. Pathogenesis of NAFLD 
2.1. NAFLD and hepatic insulin resistance 
The liver is the main site of insulin action, in addition to skeletal muscle and adipose tissue [4]. In 
the fasting state, insulin restrains hepatic glucose production which maintains plasma glucose 
concentration normal. When the liver gets fatty because of NAFLD, the ability of insulin to inhibit 
hepatic glucose production is impaired, when measured directly using a low-dose hyperinsulinemic 
euglycemic clamp combined with a glucose tracer [5] and [6]. This hepatic insulin resistance leads 
to a slight increase in plasma glucose concentrations and stimulation of insulin secretion. 
Hyperinsulinemia is likely to be the consequence rather than a cause of NAFLD, since exogenous 
insulin therapy for 7 months decreases significantly liver fat content [7]. Hyperinsulinemia could 
contribute to hypertension by stimulating basal sympathetic tone [7] and [8] and renal sodium 
reabsorption [10]. 
 
Another action of insulin is to restrain production of VLDL [11]. Hepatic insulin resistance is 
characterized by a defect in insulin inhibition of VLDL production. In subjects with NAFLD, the 
liver overproduces triglyceride-rich VLDL in the fasting state [12] and [13] and during 
hyperinsulinemia [14]. This leads to hypertriglyceridemia and a low HDL cholesterol concentration 
[15] and [16]. 
 
2.2. NAFLD vs. the metabolic syndrome in CVD 
The metabolic syndrome increases the risk of CVD approximately twofold [17]. Recently, several 
prospective epidemiological studies have shown that both increased serum liver enzyme 
concentrations [18] and [19] and hepatic steatosis determined by ultrasound [20] and [21] are able 
to predict development of CVD independent of alcohol consumption or traditional CVD risk 
factors, such as serum LDL cholesterol concentrations. In a Japanese prospective study, NAFLD 
predicted CVD better than the metabolic syndrome [20]. Multivariate analyses suggested that 
NAFLD but not the metabolic syndrome was an independent predictor of CVD [20]. 
 
2.3. NAFLD vs. the metabolic syndrome in type 2 diabetes 
Subjects with the metabolic syndrome have a four- to fivefold increased risk of type 2 diabetes as 
compared to those without the syndrome. Several studies have also shown that increased serum 
liver enzyme concentrations, the most common cause of which is NAFLD in the general population 
[22], predict type 2 diabetes independent of obesity [23]. An elegant study by Sattar et al. showed 
that prior to the onset of type 2 diabetes, fasting plasma glucose, serum ALT, and triglyceride 
concentrations increase in the absence of changes in body weight [24]. Type 2 diabetic patients 
have on the average 80% more liver fat than carefully age- and gender-matched equally obese non-
diabetic subjects [25]. These data suggest that hepatic fat accumulation is involved in the 
pathogenesis of type 2 diabetes. 
 
2.4. Pathogenesis of NAFLD: recent insights of human studies (Fig. 1) 
2.4.1. Adipose tissue 
Adipose-tissue insulin resistance, defined as insulin resistance of lipolysis, is associated with 
increased liver fat content independent of obesity in humans [13], [26] and [27]. According to stable 
isotope studies, serum FFA are the main source of hepatic triglycerides in NAFLD [28]. Adipose-
tissue insulin resistance of lipolysis is therefore likely to contribute to fat accumulation in the liver. 
In humans, PPARγ agonist (thiazolidinedione) treatment significantly decreases liver fat content by 
approximately 40%. This decrease is closely correlated with an increase in the serum concentrations 
of the adipose-tissue-derived hormone adiponectin [29]. In mice, the main target of adiponectin 
action is the liver, where it decreases insulin resistance [30]. In human fatty liver, gene expression 
of PPARγ is unaltered and that of PPARγ2 up-regulated [31]. Therefore, the decrease in the liver fat 
by PPARγ agonists cannot be mediated via liver PPARγ but might be mediated by circulating 
adiponectin. Adipose tissue has been shown to be inflamed in subjects with high as compared to 
those with low liver fat content independent of obesity [32] and [33]. This inflammation is 
characterized by increased macrophage accumulation and increased gene expression of macrophage 
markers, such as CD68, monocyte chemoattractant protein-1, and macrophage inflammatory 
protein-1α [32] and [33]. Analysis of lipid composition revealed that the inflamed adipose tissue in 
subjects with high as compared to those with low liver fat content contains more ceramides [33]. 
Ceramides are sphingolipids with a variety of metabolic functions, such as mediation of saturated 
fat-induced insulin resistance [34] and [36], inflammation, and regulation of apoptosis [37] and 
[38]. Although the mechanisms by which hepatic fat accumulation associates with adipose-tissue 
inflammation remain to be determined, macrophage infiltration and increased ceramide 
concentrations could contribute to adipose-tissue insulin resistance in NAFLD [39] and [40]. 
 
 
 
Fig. 1.  
A summary of pathogenic mechanisms, associated conditions and consequences of hepatic fat accumulation due to 
nonalcoholic causes. Please see text for references. 
 
2.4.2. De novo lipogenesis 
In humans, de novo lipogenesis produces saturated fatty acids [41] and [42]. Hepatic de novo 
lipogenesis is significantly increased in subjects with NAFLD, when measured using stable isotopes 
[28]. Hepatic gene expression of sterol regulatory element-binding protein (SREBP) 1c, key 
transcriptional activator of lipogenic genes, as well as of acetyl-CoA carboxylases (ACCs) and fatty 
acid synthase (FAS) have been shown to be increased in subjects with as compared to those without 
NAFLD [43]. Analyses of fatty acid composition revealed that the there is an excess of saturated 
fatty acids and saturated fatty acids –containing triglycerides in the human fatty liver [44]. In 
addition, the activity of a lipogenic enzyme stearoyl-CoA desaturase 1 (SCD1) is increased and the 
percentage of long polyunsaturated fatty acids decreased in subjects with as compared to those 
without NAFLD [44]. This could decrease the ability of long polyunsaturated fatty acids to inhibit 
SREBP-1c activity [45] and [46]. 
 
2.4.3. Hepatic lipids and insulin resistance 
The mechanisms underlying hepatic insulin resistance in human NAFLD have remained poorly 
characterized. We have recently shown that hepatic concentrations of diacylglycerols, the 
immediate precursors of triglycerides [47], but not of ceramides are directly related to hepatic fat 
content in the human liver [44]. Since both ceramides and diacylglycerols are able to cause insulin 
resistance by interfering with insulin signalling pathway [39] and [48], diacylglycerols rather than 
ceramides might contribute to hepatic insulin resistance in human NAFLD. 
 
2.5. Causes of hepatic fat accumulation 
2.5.1. Acquired factors 
Modest weight loss of 5–10% of body weight decreases liver fat by 40–80% in non-diabetic 
subjects and type 2 diabetic patients [49] and [51]. Weight gain of ∼10% by overfeeding of fast-
food and sedentary lifestyle in 18 young healthy subjects has been shown to increase liver fat 2.5-
fold in 4 weeks [52]. In cross-sectional studies, subjects with NAFLD have been shown to consume 
more fat, especially saturated fat [53] and [54] than subjects without NAFLD. Also, the intake of 
polyunsaturated fat has been shown to be lower in subjects with NAFLD than in those without in 
some [54] and [55] but not all [56] studies. Subjects with NAFLD tend to consume products with 
high glycemic index [57] and more soft drinks [56] as compared to subjects with a normal liver fat 
content. 
 
2.5.2. Genetic factors 
Data are emerging to suggest that genetic factors contribute to variation in liver fat content. A 
Danish twin study suggested heritability of serum ALT concentrations to be 33–48% independent 
of BMI and alcohol consumption [58]. We have recently confirmed this finding in a Finnish cohort 
of 313 twins, in which the heritability of serum ALT concentrations was 55% [59]. In the Dallas 
Heart Study, in which liver fat content was measured quantitatively using 1H-MRS, a genome-wide 
association scan revealed that the rs738409 SNP in adiponutrin gene is strongly associated with 
increased liver fat content (p = 3.4 × 10−4 in European Americans, p = 7.5 × 10−9 in African 
Americans, and p = 2.0 × 10−10 in Hispanics [60]. The other 9228 genetic variants analysed were 
not significantly associated with liver fat content [60]. 
 
3. Pathogenesis of NASH 
Only approximately 10–25% of patients with NAFLD develop NASH [63] and [64]: the factors 
responsible for the switch from steatosis to steatohepatitis have been subjects of extensive 
investigation and speculation, but currently remain elusive. The proposed “two-hits” model by Day 
and James [65] was the first attempt to provide a pathophysiological rationale to the progression of 
liver damage, claiming that the reversible intracellular deposition of triacylglycerols (TAG; “first 
hit”) leads to metabolic and molecular alterations that sensitize the liver to the “second hit”, usually 
referred to as oxidative stress and cytokine-induced liver injury. Although quite simplistic in view 
of more recent data, this model can nevertheless provide a framework to revise the main 
mechanisms involved in the pathogenesis of hepatic steatosis and its progression to steatohepatitits. 
 
3.1. “First hit”: from normal to fatty liver (Fig. 2) 
As stated before, insulin resistance is thought to be inevitably linked to the pathogenesis of NAFLD 
[66]. This condition classically involves multiple sites: the muscle, where it decreases glucose 
uptake and utilisation, the liver, where it is responsible for the overproduction of glucose despite 
fasting hyperinsulinaemia, and the adipose tissue, where lipolysis is not adequately suppressed by 
insulin, with subsequent release of glycerol and non-esterified fatty acids (NEFA) into the 
bloodstream. In addition to increased FFA efflux to the liver and increased hepatic de novo 
lipogenesis, another important source of hepatic TAG is represented by exogenous lipids. During 
the post-prandial phase, dietary lipids are transported from the gut into the bloodstream in the form 
of chylomicrons and stored in the liver, where they are processed and assembled with 
apolipoprotein B 100 (apoB100) to form very low density lipoproteins (VLDL). In overweight non-
diabetic subjects, a high-fat diet is able to promote a 35% increase of liver fat content in only 10 
days [67]. In subjects with NAFLD, dietary fat supply accounts for about 15% of intrahepatic lipid 
accumulation [28]. 
 
Fig. 2.  
Role of fatty acids in the pathogenesis of fatty liver. In NAFLD the ability of insulin to suppress lipolysis is impaired, leading to an 
increased supply of FFA to the liver; de novo synthesis of fatty acids is increased, being responsible for almost 25% of the 
increased liver fat content. The fatty acid oxidation is up-regulated, but the increase in intrahepatic fatty acid availability exceeds 
the liver's ability to oxidize excess fatty acids. Finally, subjects with NAFLD have increased rates of hepatic VLDL-triglycerides 
(TG) secretion, but a failure to increase adequately the secretion rate of apoB100, which limits the liver capacity to export  TG. 
NEFA: non-esterified fatty acids; TG: triglycerides; VLDL: very low density lipoproteins; DNL: de novo lipogenesis. 
 
Although the liver is the major organ for lipid distribution, the hepatic ability to store fat is limited 
and the lipid excess is either oxidized or released as VLDL. An increase in intrahepatic fat content 
leads to an up-regulation of oxidative mechanisms also in NAFLD patients [68], but NEFA are 
oxidized less efficiently because of mitochondrial uncoupling [69]. Subjects with NAFLD have 
increased rates of hepatic VLDL-triglycerides (TG) secretion, the major source of circulating TG, 
which is responsible for the increase in serum TG concentrations commonly observed in patients. 
However, the liver capacity to export TG is limited by an inadequate increase of the secretion rate 
of apoB100, which leads to a dissociation in VLDL-TG and VLDL apoB100 kinetics [13]. 
 
3.2. “Second hit”: from steatosis to steatohepatitis (Fig. 3) 
The progression from steatosis to steatohepatitis is likely due to the intersection of multiple 
mechanisms, probably superimposing on a genetic susceptibility to metabolic and liver damage. 
 
Fig. 3.  
NEFA induce mitochondrial dysfunction, oxidative stress, TNF-α expression and apoptosis through lysosomal destabilisation. 
NEFA: non-esterified fatty acids; TNF-α: tumour necrosis factor-alpha. 
 
Oxidative stress is increased in patients with NASH [70]. An excess of NEFA supply to the liver 
increases mithochondrial and peroxisomal β-oxidation, promotes microsomal induction of CYP4A1 
and CYP2E1 and leads to elevated production of reactive oxygen species (ROS) [71]. Increased 
levels of ROS contribute to organelle toxicity by an increase in lipid peroxidation with subsequent 
inflammation and fibrosis. 
 
Mytochondrial dysfunction and other organelle stress are observed in hepatocytes of subjects with 
steatosis. In particular, structural abnormalities in the mitochondria (megamitochondria, para-
crystalline inclusion bodies) [69] are more frequently observed in NASH than in NAFL. Moreover, 
the activity of the mitochondrial respiratory chain complexes is markedly decreased in patients with 
NASH leading to an inefficient ATP generation [72]. 
 
Although hepatic steatosis has long been considered the main cause of inflammation and liver 
damage, intracellular triglyceride storage in the liver might actually represent a mechanism to 
entrap NEFA in an inactive form, thus limiting the NEFA-induced lipid peroxidation and oxidative 
stress. This has been recently confirmed in an animal model, where the knockdown of 
diacylglycerol acyltransferase decreased hepatic steatosis by inhibiting the final step in triglyceride 
synthesis, but increased hepatic fat content, up-regulated CYP2E1, exacerbated hepatic oxidative 
damage and increased liver inflammation and fibrosis [73]. This study emphasizes the concept of 
lipotoxicity, which refers to cellular dysfunction induced by an overload of NEFA in ectopic 
tissues, such as muscle and liver. Lipotoxicity appears to be a key factor in the progression of 
hepatic steatosis to steatohepatitis by inducing an increased expression of proinflammatory 
cytokines, an inhibition of mitochondrial β-oxidation, elevated production of ROS as well as an 
enhanced generation of toxic lipid intermediates [74]. NEFA are also able to induce apoptosis in the 
hepatocyte [75]; compared to patients with simple steatosis, subjects with NASH show higher rate 
of apoptosis in the liver. Induction of the proapoptotic pathway is mediated by up-regulation of Fas 
[76], activation of Jun N-terminal kinase [75] and successive destabilisation of lysosomes [77]. 
Lysosomes have been recently proposed as primary targets of the lipotoxic effects. In an animal 
model, intrahepatic lipid accumulation by a high-fat diet induced translocation of the proapoptotic 
factor bax to the lysosome and release of lysosomal cysteine protease cathepsin B, leading to 
activation of NF-κB, increased transcription of TNF-α, increased ROS production and 
mitochondrial dysfunction [77] and [78] (Fig. 3). 
 
Other key players in the pathogenesis of steatosis and the progression to steatohepatitis are the so 
called adipokines (adiponectin, leptin, and resistin) and several cytokines (such as TNF-α, IL-6, and 
IL-1β) secreted by the adipocyte or by the inflammatory cells that infiltrate the adipose tissue in 
insulin-resistant states. Visceral adipose tissue represents a preferential source of adipokines and 
cytokines potentially acting on the liver tissue. The adipokines exert both metabolic and immune 
functions and mediates the metabolic cross-talk between adipose tissue, muscle and liver. Some of 
them, as adiponectin, possess anti-inflammatory and anti-inflammatory properties, while others, as 
TNF-α and leptin, have an opposite action. The liver damage in NASH could result from an 
imbalance between pro- and anti-inflammatory adipokines. In fact, adiponectin plasma levels are 
decreased in NAFLD patients and inversely related to hepatic insulin resistance, hepatic fat content 
[79], degree of inflammation [80] and extent of fibrosis in the liver [81]. High TNF-α and low 
adiponectin plasma levels have been indicated as independent predictors of NASH in NAFLD 
patients [80]. 
 
On the contrary, serum levels of resistin are increased in patients with NASH and correlated with 
hepatic insulin resistance, hepatic fat content [82] and the histological inflammatory grade [83]. 
 
Leptin is a key mediator in the development of insulin resistance, hepatic steatosis and liver 
damage. In patients with NASH serum leptin levels were positively correlated with hepatic fat 
content, fibrosis and inflammation, as well as with serum lipids, glucose, insulin, C-peptide and 
ALT [84]. Leptin down-regulates insulin signalling in the liver [85], and favours the development 
and progression of fibrosis [86]. 
 
Cytokines, particularly TNF-α, IL-6, and IL-1β, are involved in the recruitment and activation of 
Kupffer cells and the transformation of stellate cells into myofibroblasts, both of which contribute 
to the progression from steatosis to steatohepatitis. They can also affect insulin signalling, thus 
playing a role in the development of insulin resistance [87]. 
 
Insulin resistance per se and the subclinical inflammatory state usually associated with it might have 
a direct role in the pathogenesis of liver injury. Hyperglycemia and hyperinsulinemia can cause an 
up-regulation of the tissue connective growth factor, thus promoting fibrogenesis [88]. In obese, 
diabetic rats a high-fat diet enhances insulin resistance and leads to severe steatohepatitis via an up-
regulation of genes for lipogenesis (sterol regulatory element-binding protein-1c, SREBP-1c, fatty 
acid synthase, FAS), inflammation (IL-6, TNF-α) and fibrogenesis (transforming growth factor-
beta, TGF-β) [89]. 
 
3.3. Predictive factors of advanced fibrosis in NAFLD 
Various clinical and laboratory markers were shown to be associated with advanced fibrosis in 
patients with NAFLD (Table 1). The need of a non-invasive test able to accurately distinguish 
NASH from NAFL has led several investigators to combine some clinical and laboratory variables 
in order to create surrogate markers of advanced disease. By analysing a large cohort of biopsy-
proven NAFLD subjects, Angulo et al. generated a NAFLD fibrosis score composed of six readily 
available variables (age, BMI, hyperglycemia, platelet count, albumin, AST/ALT ratio), to 
discriminate patients with or without severe fibrosis. This score accurately predicts the presence or 
the absence of advanced fibrosis in about 75% of NAFLD patients [90]. More recently, the 
European Liver Fibrosis study group validated the ELF score, made up of a combination of three 
components of the extracellular matrix (serum hyaluronic acid, amino-terminal propeptide of type 
III collagen and tissue inhibitor of metalloproteinase 1). This algorithm has shown a good 
performance in differentiating fibrosis stages in NAFLD, with a better accuracy when combined 
with the NAFLD fibrosis score (over 90% in distinguishing severe fibrosis) [91]. However, all these 
scores are not still employed in routine clinical practice. 
 
Table 1. 
Predictive factors for advanced fibrosis in retrospective and follow-up studies, respectively. 
 Retrospective (n = 17) Follow-up (n = 5) 
Obesity/BMI/weight gain 7 3 
Diabetes/high glucose 5 2 
High insulin/insulin resistance/metabolic syndrome 10 2 
Ferritin 2 – 
Age 3 1 
High triglycerides 2 – 
Male gender 1 – 
Female gender 1 – 
ALT > 2× or AST/ALT > 1 7 1 
 
3.4. Nuclear receptors in the pathogenesis of NAFLD and NASH 
Homeostatic regulation of lipid metabolism requires cellular sensors that can monitor the 
concentration of bioactive lipids and coordinate the enzymatic cascades that regulate lipid synthesis 
and catalysis. On this regard, the nuclear receptors are transcription factors that serve as 
intracellular sensors for endocrine hormones and dietary lipids, and have emerged as key regulators 
of lipid and carbohydrate metabolism [93] and [94]. In contrast to extracellular receptors, which 
bind to peptide ligands (e.g., growth factors and insulin) at the cell surface and activate cytoplasmic 
kinase cascades, nuclear receptors interact directly with lipophilic ligands and regulate expression 
of target genes. Nuclear receptors function as ligand-dependent transcription factors by binding to 
specific DNA sequences called response elements within the regulatory regions of target-gene 
promoters and activate target-gene expression [93]. 
 
The retinoid X receptor (RXR) represents a common binding partner for other nuclear receptors to 
form an heterodimer. The ability of RXR agonists to regulate target genes of multiple permissive 
partners implies that in vivo such compounds may have pharmacologic use as panagonists of 
several metabolically important pathways, although this advantage is likely to be offset by poor 
selectivity. In addition, the propensity of RXR agonists to induce hypertriglyceridemia in animals 
and humans indicates that targeting the heterodimeric partners of RXRs is likely to result in more 
suitable candidates for drug therapy [93]. 
 
3.5. Farnesoid X receptor (FXR), lipid metabolism and chronic liver disease 
FXR is a bile acid sensor that acts as an RXR heterodimer and functions to protect cells and organs, 
especially the liver and the intestine, against bile acid toxicity [95], [96] and [97]. Bile acids are the 
major ligands for FXR, and by activating FXR have a variety of transcriptional effects, many of 
which are geared toward preventing synthesis and uptake and promoting excretion of bile acids. 
One effect of FXR activation is downregulation of Cyp7A1 and thus bile acid synthesis, 
accomplished through induction of SHP (short heterodimer partner) which then represses Cyp7A1 
transcription. A second effect of FXR activation is downregulation of the hepatic bile acid import 
pumps NTCP and OATP (Na-dependent taurocholate cotransporting polypeptide and organic anion 
transporting polypeptide), thus reducing the import of bile acids from the plasma compartment into 
the hepatocyte. A third effect of FXR activation is up-regulation of the hepatic bile acid export 
pumps BSEP and MRP2 (bile salt export protein and multidrug resistance-associated protein-2), 
thus increasing the export of bile acids out of the hepatocyte into the bile. A fourth effect of FXR 
activation is the induction of pathways responsible for detoxification of bile acids. 
 
It has been known for many years that the bile acid pool size has a profound effect on lipid 
metabolism. The reduced bile acid pool, following either administration of bile acid binding resins 
(e.g., cholestyramine or cholestipol) or ileal surgery, results in reduced levels of plasma LDL and 
increased plasma triglyceride and HDL. The finding that administration of bile acids (CDCA or 
CA) to humans or animals results in reduced plasma triglyceride and HDL levels and increased 
LDL is entirely consistent with a key role for bile acids in controlling plasma lipids [98]. 
 
Studies with Fxr−/− mice or following administration of FXR-specific agonists have demonstrated 
that FXR plays a central role in controlling lipid homeostasis, by reducing both hepatic lipogenesis 
and plasma triglyceride and cholesterol levels. FXR activation induces genes involved in 
lipoprotein metabolism/clearance and represses hepatic genes involved in the synthesis of 
triglycerides. For example, treatment of mice with FXR agonists results in the repression of Srebp-
1c mRNA levels in murine livers or isolated murine primary hepatocytes [99] and [100]. This 
repression was not observed with Shp−/− mice, suggesting that SHP, a known FXR target gene, is 
required for the repression [99]. Since SREBP-1c functions as a critical transcription factor that 
regulates many genes involved in both fatty acid and triglyceride synthesis [94], it is not surprising 
that hepatic triglyceride synthesis and secretion is reduced following the repression of Srebp-1c by 
FXR. 
 
Activation of FXR also results in increased hepatic expression of receptors (VLDL receptor and 
syndecan-1) that are involved in lipoprotein clearance and in decreased expression of proteins 
(apoC-III and ANGTPL3) that normally function as inhibitors of lipoprotein lipase [101]. Finally, 
FXR induces human PPARα [102], a nuclear receptor that functions to promote fatty acid β-
oxidation (see below). Taken together, these data suggest that FXR activation lowers plasma 
triglyceride levels via both repressing hepatic lipogenesis and triglyceride secretion, and increasing 
the clearance of triglyceride-rich lipoproteins from the blood. 
 
Nevertheless, the ultimate proof for the FXR pivotal role in lipid homeostasis was offered by the 
generation of FXR−/− mice. These mice accumulate fat in the liver and, together with changes in 
bile acid homeostasis, they show a pro-atherogenic lipid profile (elevated TG and cholesterol 
plasma levels) as a direct consequence of the FXR absence [103]. The observation that Fxr−/− mice 
have increased plasma LDL and HDL levels is consistent with an important role for FXR in 
controlling plasma lipoprotein levels. As stated above, FXR controls cholesterol metabolism mostly 
through expressional modulation of CYP7A1, the rate-limiting enzyme for cholesterol catabolism 
into bile acids. When the bile acid pool size increases, FXR activation leads to repressed expression 
of Cyp7a1. Downregulation of CYP7A1 by FXR would lead to decrease cholesterol catabolism 
with net accumulation of the sterol in the liver and in the plasma. In line with this issue, 
pharmacological inhibition of FXR by antagonist molecules is a promising approach to enhance 
cholesterol conversion into bile acids, hence decrease cholesterol levels in plasma. However, the 
story is not as simple as it seems. FXR knockout mice, in fact, display increased intestinal 
absorption of cholesterol, suggesting a negative regulatory role for FXR on cholesterol absorption 
in the intestine [104]. Also, FXR might act as an enhancer of reverse cholesterol transport, the 
process of cholesterol delivery from peripheral tissues to the liver for biliary disposal [104]. 
Overall, the role of FXR agonism–antagonism in cholesterol disposal and HDL cholesterol plasma 
levels is still controversial, and contradictory data in the literature provide the impetus to address 
this critical issue in the next future. 
 
Fxr−/− mice show impaired glucose tolerance and insulin sensitivity compared to wild-type mice. 
Hyperinsulinemic–euglycemic clamp studies reveal that Fxr−/− mice also display insulin resistance 
in the liver, muscle and white adipose tissue [105] and [106]. Treatment of mice with the FXR 
agonist GW4064 or cholic acid, or following infection with adenovirus that expresses a 
constitutively active FXR-VP16 fusion protein, resulted in a significant reduction of plasma glucose 
levels and improved insulin sensitivity [105], [106] and [107]. These effects were noted in three 
different diabetic models (db/db, ob/ob or KK-Ay mice). Activation of hepatic FXR regulates 
gluconeogenesis, glycogen synthesis and insulin sensitivity. Overall, these changes result in 
decreased hepatic gluconeogenesis, decreased plasma glucose levels and increased hepatic glycogen 
synthesis. FXR activation also results in increased phosphorylation of hepatic IRS-1 and IRS-2 and 
increased insulin sensitivity/signalling [100]. The finding that activation of FXR significantly 
lowered plasma glucose, triglyceride, cholesterol and free fatty acid levels in diabetic mouse models 
[106], suggests that FXR agonists might prove useful in the treatment of hyperglycemia and 
hyperlipidemia that are observed in patients with type 2 diabetes. 
 
The concerted actions of FXR on lipid and glucose metabolism indicate that FXR contributes to the 
coordinated regulation of the shift from the fasted to fed transition by interfering with lipid- and 
carbohydrate-induced changes in gene expression. In the post-prandial state, BAs secreted into bile 
and discharged into the intestine stimulate absorption of lipids that form chylomicrons in lymph. 
Carbohydrates, like glucose, are absorbed and reach the liver via the portal vein. BAs undergo 
enterohepatic recirculation and return to the hepatocyte where they activate, among other actions, 
FXR. Activated Fxr subsequently interferes with glycolysis, to stimulate glycogen storage, and 
inhibits de novo lipogenesis. Finally, FXR inhibits BA synthesis by inhibition of Cyp7a1 
expression. Thus, FXR participates in the metabolic adaptation of the hepatocyte in the post-
prandial state [108]. 
 
As mentioned above, FXR is thought to play a substantial role in liver diseases in light of its ability 
to affect bile acid homeostasis. A potential role of FXR in chronic cholestatic diseases is suggested 
by reduced FXR expression observed in patients affected by progressive familial intrahepatic 
cholestasis type 1. FXR activation could be beneficial in chronic cholestatic disorders by re-
establishing a proper bile acid excretion and bile formation and by activating phase 1 and phase 2 
detoxifying enzymes. Many of these findings, however, are from experimental animal models that 
not fully recreate human diseases, thus expectations are yet to be verified [98]. Activation of PXR 
(that shares similar functions with FXR) resulted not effective in ameliorating cholestatic injury in 
patients with primary biliary cirrhosis [109]. Activation of FXR by the synthetic agonist GW4064 
reduced neutral lipid accumulation in the livers of db/db mice [106]. However, UDCA was not 
associated with an improvement in serum liver biochemistries or histology when compared with 
placebo [110]. 
 
Exposure to routinely measured concentrations of BAs increases HCV replication by a novel 
mechanism involving activation of the nuclear-receptor FXR. In addition, HSC exposure to BA 
concentrations found in chronic cholestatic conditions induces cell proliferation through EGF 
receptor activation [111]. FXR has been also found to enhance liver regeneration and cell 
proliferation. If this aspect may be beneficial in certain diseases, a potential tumourigenic effect of 
FXR needs to be ruled out before considering a long term administration of its agonists to patients 
with chronic liver diseases [98]. 
 
3.6. Peroxisome-proliferator-activated receptors (PPARs) 
The peroxisome-proliferator-activated receptors (PPARs) are a subfamily of the nuclear-receptor 
superfamily and regulate gene expression in response to ligand binding. After ligand binding, 
PPARs undergo specific conformational changes that allow for the recruitment of one coactivator 
protein or more. 
 
PPARs regulate gene transcription by two mechanisms. As already mentioned, transactivation is 
DNA-dependent and involves binding to PPAR response elements of target genes and 
heterodimerisation with RXR. A second mechanism, transrepression, may explain the anti-
inflammatory actions of PPARs. It involves interfering with other transcription-factor pathways in a 
DNA-independent way [112]. Various fatty acids serve as endogenous ligands for PPARs, and three 
PPARs, designated PPARα, PPARγ, and PPARδ have been identified to date with different effects 
in terms of gene expression, as summarized in Fig. 4. 
 
 
 
Fig. 4.  
A summary of the different cellular effects of PPARs, associated to several aspects of cell metabolism and proliferation. Please 
see text for references. 
 
PPARα: The gene encoding PPARα was initially cloned from mouse liver cDNA on the basis of its 
properties as a nuclear-receptor activated by carcinogens that induce peroxisome proliferation in the 
liver [113]. PPARα, which recognizes monounsaturated and polyunsaturated fatty acids and 
eicosanoid is predominantly expressed in the liver, brown fat and heart, and has been implicated in 
regulating cellular energetics [93]. As such, many PPARα target genes are involved in 
mitochondrial and peroxisomal β-oxidation of fatty acids [93]. Numerous studies of PPARα−/− 
mice have shown that fasting or high-fat feeding of these mice results in abnormal lipid 
accumulation in hepatocytes, which is consistent with a crucial role for PPARα in hepatic lipid 
metabolism [114] and [115]. In addition, in normal rats, high-fat feeding-induced steatosis was 
related to PPARα downregulation, presumably mediated by increased circulating free fatty acid 
[116]. 
 
PPARα is expressed in human and mouse immune cells, including lymphocytes, macrophages and 
dendritic cells. Numerous studies have implicated PPARα in the negative regulation of 
inflammatory responses. How PPARα influences inflammatory gene expression remains 
incompletely understood. Several mechanisms are known to be involved, including direct 
interactions with the transcription factors NF-κB and AP1, alterations in cytokine-receptor and 
growth factor receptor signalling, and up-regulation of expression of a subunit of inhibitor of NF-
κB (IκB) [117]. Given that PPARα regulates numerous genes and mechanisms involved in lipid 
metabolism and inflammation, it could be beneficial in the pathogenesis of NASH. Supplementation 
of n-3 polyunsaturated fatty acid, a PPARα ligand, to HFD-treated animals restored hepatic 
adiponectin and PPARα expression, reduced TNFα hepatic levels, and ameliorated fatty liver and 
the degree of liver injury [116]. In patients with NAFLD, supplementation with n-3 polyunsaturated 
fatty acid reduced hepatic steatosis and transaminase value [118]. Furthermore, in wild-type mice, 
HFD significantly increased the hepatic and adipose expression of numerous genes involved in 
inflammation. This effect was amplified in PPARα−/− mice and reduced in wild-type by treatment 
with the PPARα ligand Wy-14643, suggesting an anti-inflammatory role of PPARα in liver and 
adipose tissue [115]. In agreement with this, in a model of NASH, tranilast (that inhibits the action 
of the fibrogenic transforming growth factor-beta, TGF-β) attenuated hepatic inflammation, down-
regulated TNF-α expression, and up-regulated PPARα [119]. Following high sucrose diet, a 
pharmacological IKK2 inhibitor attenuated the inflammatory response both in the adipose tissue 
and in the liver, and improved lipid β-oxidation mediated by PPARα [120]. Liver-specific 
inactivation of the NF-κB essential modulator gene (NEMO) synergizes with an HFD in the 
development of liver steatosis as a consequence of decreased PPARα and increased PPARγ 
expression. Steatosis interacts with increased inflammation, causing elevated apoptosis in the livers 
of these mice under HFD [121]. 
 
In other forms of chronic liver injury, the role of PPARα is more than complex. Hepatic 
concentrations of PPARα and its downstream target-gene CPT1A expressed by hepatocytes were 
impaired profoundly in the livers of untreated patients with HCV infection compared with controls 
[122]. In mice, liver-specific transgenic expression of the HCV core protein induced hepatic 
steatosis in all animals and HCC development in 35% of them [123]. 
 
PPARγ: PPARγ is expressed most abundantly in adipose tissue but is also found in pancreatic β 
cells, vascular endothelium, and macrophages. Its expression is low in tissues that express 
predominantly PPARα, such as the liver, the heart, and skeletal muscle [124]. PPARγ is essential 
for normal adipocyte differentiation and proliferation as well as fatty acid uptake and storage. The 
PPARγ genetic program includes target genes involved in the uptake of glucose in muscle (c-Cbl 
associated protein and glucose transporter 4), lipid metabolism thus reducing the hepatic supply of 
fatty acids from adipose tissue and increasing β-oxidation by AMPK activation, and energy 
expenditure (glycerol kinase and uncoupling proteins 2 and 3) [93], [94], [124] and [125]. A range 
of naturally occurring ligands can activate PPARγ, including unsaturated fatty acids, eicosanoids 
and components of oxidized LDLs. In addition, PPARγ is the molecular target of 
thiazolidinediones, which sensitize cells to insulin and are in clinical use for their antidiabetic 
effects in the liver, adipose tissue and skeletal muscle. Possible mechanisms of PPARγ-induced 
insulin sensitivity include increased lipid uptake and storage, leading to decreased free fatty acids 
and serum triglycerides, suppression of hepatic gluconeogenesis, and a small contribution toward 
increased uptake of glucose by adipose tissues [124]. 
 
Thiazolidinediones firstly promote fatty acid uptake and storage in adipose tissue. In this way, they 
increase adipose-tissue mass and spare other insulin-sensitive tissues such as skeletal muscle and 
the liver, and possibly pancreatic β cells, from the harmful metabolic effects of high concentrations 
of free fatty acids. By keeping fat where it belongs. thiazolidinediones increase hepatic insulin 
sensitivity (the ability of insulin to suppress endogenous glucose production) and insulin sensitivity 
in adipose tissue (measured from the ability of insulin to suppress free fatty acid concentrations) 
[126]. Thiazolidinediones might also modulate insulin sensitivity indirectly, by means of altered 
adipokine release able to regulate insulin sensitivity outside adipose tissue, such as resistin, 
adiponectin, and TNF-α [124]. 
 
In addition to transcriptional activation, an important function of PPARγ is to inhibit inflammatory 
gene expression in a signal-specific manner. This process is termed transrepression because 
inhibition does not depend on the binding of PPAR–RXR heterodimers to PPREs in target-gene 
promoters. Numerous studies have shown that administration of PPARγ ligands can ameliorate 
inflammatory responses in the pancreas, lungs, joints, nervous system and gastrointestinal tract, 
suggesting a therapeutic potential for PPARγ agonists that selectively modulate inflammation [127]. 
In the liver, PPARγ ligands have been shown to restore the quiescent phenotype of hepatic stellate 
cells in culture and to reduce activated stellate cell numbers in rodent models of fibrosis and NASH 
[128], [129] and [130]. All of these effects could reduce hepatic fat accumulation and related 
inflammation in NASH. This is probably the reason why thiazolidinediones have received great 
attention in the therapy of NASH. A recent proof-of-concept study showed a reduction in both 
hepatic fat and inflammation in diabetic NASH patients taking pioglitazone. In addition 
pioglitazone reduced insulin and free fatty acid levels, indicating improved insulin sensitivity in the 
peripheral and adipose tissue. Remarkably pioglitazone did not affect the degree of fibrosis, 
presumably due to the short period (6 months) of the study [131]. When the treatment with 
pioglitazone was extended to 12 months in non-diabetic NASH patients, a significant reduction in 
the degree of hepatic fibrosis was also observed [132]. On the other hand, a further recent using 
rosiglitazone, showed a reduction in insulin resistance and hepatic steatosis, without improvement 
in other histological parameters [133]. 
 
PPARδ: PPARδ (also known as PPARβ) is ubiquitously expressed, suggesting a fundamental 
requirement for PPARδ signalling in many tissues [93] and [117]. Dietary fatty acids (FAs) carried 
by VLDL have been shown to activate PPARδ. PPARδ controls many metabolic programs in 
glucose and fatty acid homeostasis through direct transcriptional regulation, while its activity in 
suppressing inflammatory response is believed to be indirect. Pharmacological or genetic activation 
of PPARδ exerts many therapeutic effects, including reducing hepatic glucose production, 
increasing fatty acid catabolism in adipocyte and muscle, lowering the atherogenic mechanisms 
[117]. In animal models, these effects lead to attenuation of metabolic syndrome, such as obesity, 
dyslipidemia and insulin resistance [134]. 
 
It has been proposed that the glucose lowering effect is mediated, in part, by metabolizing glucose 
for lipogenesis in the liver [135]. Thus, the lipogenic activity in the liver can be a concern as hepatic 
steatosis is common in diabetic patients. However the PPARδ ligand GW501516 reduced fatty liver 
un high-fat fed C57BL/6 mice, and decreased hepatic TG and inflammation in a mouse model of 
nonalcoholic steaohepatitis (NASH) induced by a diet deficient in methionine and choline [123] and 
[136]. Collectively, these findings suggest that PPARδ is a potential therapeutic target for insulin 
resistance and hepatic steatosis. 
 
4. Conclusions 
Nonalcoholic fatty liver disease (NAFLD) comprises a disease spectrum which includes variable 
degrees of simple steatosis (nonalcoholic fatty liver, NAFL), nonalcoholic steatohepatitis (NASH) 
and cirrhosis. NAFLD can be considered the hepatic manifestation of the metabolic syndrome that 
recognizes insulin resistance as the main pathogenetic mechanism. Thus, NAFLD represents a risk 
factor for cardiovascular diseases. In addition, NAFLD represents the more common cause of 
chronic liver disease. However, no specific therapies for NAFLD, and its progressive form NASH, 
are currently available. In recent years, an outstanding number of studies have better defined the 
pathogenetic mechanisms that regulate the shift from NAFLD to NASH. On this regard, an 
exhaustive description of the cross-talk between visceral adipose tissue and the liver, in terms of 
adipokines, cytokines and growth factors, has been provided to explain the chronic inflammatory 
state associated to the metabolic syndrome. Adipokines, cytokines and growth factors can modify 
hepatic metabolism by acting on specific nuclear receptors that could represent the target of specific 
drug therapies. 
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